FDA Pushes Back Axogen Avance Nerve Graft Decision By 3 Months FDA delays Axogen's Avance Nerve Graft BLA review to December 5, after new data submission, while the company raises its full-year revenue outlook.
Why Axogen Stock, Up 76% Over The Last Two Months, Just Plummeted The FDA's move is largely procedural, says one analyst, but it adds incremental uncertainty.
Which stocks are moving before the opening bell on Monday? Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.
Axogen Inc (NASDAQ:AXGN) Surges 15.8% After Q2 2025 Earnings Beat and Raised Guidance Axogen Inc (AXGN) surpasses Q2 2025 estimates with strong revenue and EPS growth, raises full-year guidance, sparking a 15.8% pre-market stock surge.
These stocks are moving in today's pre-market session The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
These stocks are moving in today's after hours session Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
Which stocks are gapping on Thursday? Let's delve into the US markets on Thursday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
AXGN Stock Earnings: Axogen Beats EPS, Beats Revenue for Q2 2024 AXGN stock results show that Axogen beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
AXGN Stock Earnings: Axogen Beats EPS, Misses Revenue for Q1 2024 AXGN stock results show that Axogen beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Why SOPHiA GENETICS Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session Shares of SOPHiA GENETICS SA (
NASDAQ: SOPH ) fell sharply during Tuesday’s session after the company reported worse than expected fourth-quarter earnings and issued 2024 guidance.
